First-Line Breast Cancer Approval: Gilead's TROP-2 Trodelvy and Keytruda Combination Secures FDA Nod

First-Line Breast Cancer Approval: Gilead’s TROP-2 Trodelvy and Keytruda Combination Secures FDA Nod